Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors. Specifically, disclosed are hydrochloride and acetate of compounds of formula (I) and crystal forms thereof, as well as application of the salt types and the crystal forms in preparation of RHO inhibitor drugs.

##STR00001##

A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.

A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.

Novel compounds, in particular novel peroxisome proliferator-activated receptor (PPAR) agonist compounds, are provided. Pharmaceutical formulations for treating PPAR mediated disorder or condition are also provided. The formulations may be a combination of cannabinoids and the PPAR agonist compounds. The PPAR mediated disorder or condition may include inflammation related diseases such as psoriasis, psoriatic arthritis and atopic dermatitis.

Novel compounds, in particular novel peroxisome proliferator-activated receptor (PPAR) agonist compounds, are provided. Pharmaceutical formulations for treating PPAR mediated disorder or condition are also provided. The formulations may be a combination of cannabinoids and the PPAR agonist compounds. The PPAR mediated disorder or condition may include inflammation related diseases such as psoriasis, psoriatic arthritis and atopic dermatitis.

Novel compounds, in particular novel peroxisome proliferator-activated receptor (PPAR) agonist compounds, are provided. Pharmaceutical formulations for treating PPAR mediated disorder or condition are also provided. The formulations may be a combination of cannabinoids and the PPAR agonist compounds. The PPAR mediated disorder or condition may include inflammation related diseases such as psoriasis, psoriatic arthritis and atopic dermatitis.

The present invention provides compounds of formula I: ##STR00001##
or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.

The present invention provides compounds of formula I: ##STR00001##
or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.

The present invention relates to seco (opened ring) macrolide compounds, to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents.

The present invention relates to seco (opened ring) macrolide compounds, to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents.